Experimental Drug Targets Key Cancer Proteins

Researchers at Roswell Park Comprehensive Cancer Center have reported that the investigational compound FL118 functions as a dual molecular glue degrader, directly targeting and eliminating two proteins associated with tumor survival. The findings outline a novel therapeutic approach that simultaneously addresses multiple cellular pathways involved in malignant progression, offering a potential alternative to conventional single-target cancer drugs.

FL118 specifically binds to and degrades DDX5 and UbE2T, proteins that have recently emerged as critical factors in cancer cell viability and treatment resistance. By acting as a molecular glue, the compound facilitates the recruitment of the cell’s natural degradation machinery to these targets, effectively removing them from the cancer cell environment. This dual-targeting mechanism may help disrupt adaptive survival responses that tumors frequently